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ABSTRACT 
Background/Aims: HCV reinfection following successful treatment can compromise 
treatment outcome. This systematic review assessed the rate of HCV reinfection following 
treatment among people with recent drug use and those receiving opioid agonist therapy 
(OAT). 
Methods: Bibliographic databases and conference abstracts were searched for studies 
assessing post-treatment HCV reinfection rate among people with recent drug use (injecting 
or non-injecting) or those receiving OAT. Meta-analysis was used to cumulate reinfection 
rates and meta-regression to explore heterogeneity. 
Results: Thirty-six studies were included (person-years follow-up=6,311). The overall rate of 
HCV reinfection was 5.9/100 person-years (95%CI: 4.1-8.5) among people with recent drug 
use (injecting or non-injecting), 6.2/100 person-years (95%CI: 4.3-9.0) among people 
recently injecting drugs, and 3.8/100 person-years (95%CI: 2.5-5.8) among those receiving 
OAT. Reinfection rates were comparable following interferon-based (5.4/100 person-years; 
95%CI: 3.1-9.5), and direct-acting antiviral therapy (3.9/100 person-years; 95%CI: 2.5-5.9). 
In stratified analysis, reinfection rate was 1.4/100 person-years (95%CI: 0.8-2.6) among 
people receiving OAT with no recent drug use, 5.9/100 person-years (95%CI: 4.0-8.6) among 
people receiving OAT with recent drug use, and 6.6/100 person-years (95%CI: 3.4-12.7) 
among people with recent drug use, not receiving OAT. In meta-regression analysis, longer 
follow-up was associated with lower reinfection rate [adjusted Rate Ratio (aRR) per year 
increase in mean/median follow-up: 0.77, 95%CI: 0.69-0.86]. Compared with people 
receiving OAT with no recent drug use, those with recent drug use, receiving OAT (aRR: 
3.50, 95%CI: 1.62-7.53), and those with recent drug use, not receiving OAT (aRR: 3.96, 
95%CI: 1.82-8.59) had higher reinfection rates. 
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Conclusion: HCV reinfection risk following treatment increased among people with recent 
drug use compared to those receiving OAT. Lower rates in studies with longer follow-up 
suggested higher reinfection risk early post-treatment.  
 
Word counts: 275 words 
 
 
Lay summary  
Our findings demonstrate that although reinfection by hepatitis C virus following successful 
treatment occurs among people with recent drug use, the rate of hepatitis C reinfection is 
lower than rates of primary infection that have been r ported in the literature in this 
population and it should not be used as a reason to withhold therapy from people with 
ongoing injecting drug use. The rate of hepatitis C reinfection was lowest among people 
receiving opioid agonist therapy with no recent drug use, compared to people with recent 
drug use. These data illustrate that harm reduction services are required to reduce the 
reinfection risk, while regular post-treatment hepatitis C assessment is required for early 
detection and retreatment. 
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INTRODUCTION 
Globally, among the 71 million people living with hepatitis C virus (HCV) [1], 6.1 million 
(8.6%) injected drugs during the previous year [2]. HCV transmission continues to occur 
among people who have recently injected drugs [3-6]. Increasing access to HCV prevention 
services and HCV treatment among people who inject drugs will be critical to achieve the 
World Health Organization goal of eliminating HCV as  major global public health threat by 
2030 [7]. 
 
Direct-acting antiviral (DAA) therapy for HCV infection is effective among people who have 
recently injected drugs [8]. In many countries, peopl  who have not ceased injecting drug use 
are ineligible to receive HCV treatment, either because of clinical guidelines or due to 
restrictions for government reimbursement of therapy [9, 10]. A major concern is that 
ongoing injecting risk behaviours following DAA therapy may lead to HCV reinfection, 
reversing the benefit of cure [11]. Given that DAA therapy is expensive, data on the 
magnitude of post-treatment HCV reinfection risk is crucial to guide clinical decision making 
and policy in this area. 
 
Although there have been three systematic reviews evaluating the rate of HCV reinfection 
among people who inject drugs [12-14], there is only one performed in the DAA era 
(included five studies) [13]. These systematic reviews are limited by the inclusion of studies 
with heterogeneous study populations, small numbers of identified studies, limited sub-group 
analysis, and lack of data on persistent HCV reinfection. To our knowledge, there has been 
no published meta-regression analysis to assess the study-level factors associated with HCV 
reinfection rate.  
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The aim of this systematic review was to evaluate the rate of HCV reinfection following 
successful HCV treatment (interferon-based and DAA) among well-defined populations of 
individuals with recent drug use, including those with recent injecting drug use, and 
individuals receiving OAT. Factors explaining heterogeneity across studies were also 
assessed. 
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METHODS 
This study is reported based on the PRISMA statement [15]. Study protocol was registered 
with PROSPERO (PROSPERO 2018 CRD42018114765). 
 
Eligibility criteria 
We included prospective and retrospective studies, investigating HCV reinfection following 
HCV treatment, if they met all the following criteria: 
a) Study population included defined populations of peopl  with recent drug use or 
people receiving OAT 
b) Reinfection following treatment-induced HCV clearance (interferon-based or DAA 
therapy) was assessed 
c) Reinfection rate, including person-years follow-up was reported.  
 
Studies including participants with former or current drug use were included when the data 
specifically for those with recent drug use were avail ble. “Recent drug use” was considered 
as injecting or non-injecting drug use within six months prior to treatment initiation, during 
treatment, at the end of treatment, or during post-treatment follow-up. Other definitions 
referring to active drug use at the time of study entry were also accepted for inclusion. 
Studies with <10 person-years follow-up were excluded. 
 
Information sources and search 
Literature searches of five bibliographic databases, including MEDLINE (Pubmed), Scopus, 
Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO 
were performed. Presentations at the key viral hepatitis conferences were searched, including 
International Liver CongressTM, The Liver Meeting®, Annual Conference on Retroviruses 
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and Opportunistic Infections (CROI), and International Symposium on Hepatitis Care in 
Substance Users (INHSU). ClinicalTrials.gov was searched for unpublished or ongoing 
studies. Reference lists of the articles included in the analysis, and relevant review articles 
were hand searched. Forward citation tracking was carried out, using Scopus. Searches were 
performed in October 2018, and updated in June 2019. No time restriction was applied for the 
search results.  
 
The details of the search strategies are provided in Supplementary Table 1. In brief, 
combinations of search terms were used, relating to HCV, drug use, OAT, HCV treatment, 
and reinfection/reviraemia.  
 
Study selection 
The records found through primary search were initially screened by title and abstract. The 
full-text of potentially eligible records were reviwed, and eligible studies were selected for 
inclusion (Figure 1). In the case of multiple publicat ons of one study, the one with the most 
updated data was included. 
 
Data collection process and data items 
Required data were extracted into a standardized spreadsheet. The extracted data included the 
items related to study design and setting, definitio  of recent drug use and OAT, study 
participant characteristics, HCV treatment, post-treatment follow-up, and HCV reinfection 
(Table 1). Authors were contacted if supplementary data were required.  
 
Risk of bias in individual studies 
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The risk of bias for the included studies was assessed using a modified scale derived from 
Newcastle-Ottawa quality assessment scale for cohort studies [16], including eight items with 
a total score of nine (Supplementary Table 2). Studies with a score of <6, 6–7, and >7 were 
considered as having high, moderate, and low risk of bias, respectively. 
 
Two or more reviewers independently carried out title/abstract screening (EC, HV), full text 
review (BH, EC, JG), data extraction (BH, EC, HV), and critical appraisal (BH, EC, HV, JG), 
with discrepancies discussed in the group to reach consensus. 
 
Synthesis of results 
The primary outcome was the rate of HCV reinfection. The secondary outcome was the rate 
of persistent HCV reinfection. HCV reinfection was defined as the detection of HCV RNA 
following an end of treatment response (i.e., non-quantifiable HCV RNA at the end of 
treatment) or following sustained virologic response [SVR, i.e., non-quantifiable HCV RNA 
at 12 (SVR12) or 24 (SVR24) weeks after the end of treatment]. In studies using end of 
treatment to indicate the beginning of the time at risk for HCV reinfection, HCV RNA 
recurrence was considered as reinfection if HCV sequencing or genotype data were used to 
confirm detection of infection with an HCV strain, subtype or genotype distinct from the 
virus prior to treatment. In the studies using SVR to indicate the beginning of the time at risk 
for HCV reinfection, any HCV RNA recurrence was considered as reinfection, given the low 
likelihood of viral relapse after SVR [17, 18]. Persistent HCV reinfection refers to the 
detection of HCV RNA at least 24 weeks following reinf ction. For each included study, the 
rate of HCV reinfection was calculated, using the reported number of reinfection cases and 
person-years follow-up. A fixed continuity correction of 0.5 was applied in studies with no 
cases of reinfection. Log transformed rates were used in all analyses, and back-transformed 
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for reporting. Heterogeneity across studies was assessed using the I-square statistic, with an I-
square <25%, 25%-75%, and >75% considered as low, moderate, and high heterogeneity, 
respectively [19]. Random effect meta-analysis models were used to cumulate the rate 
estimates.  
 
Study-level factors contributing to heterogeneity of the outcome were assessed using 
stratified analysis and meta-regression. Stratified analyses were performed by HCV treatment 
(interferon-based, versus DAA therapy), risk of bias, nd exclusive study population risk 
groups (based on recent drug use and OAT status). In studies combining populations of 
people with recent drug use and people receiving OAT, sub-population data were used in the 
risk group analyses. 
 
In meta-regression, the covariates were determined a priori and included study design, study 
setting, study population risk groups, participants’ mean/median age, proportion of men, 
proportion with HIV co-infection, HCV treatment, mean/median post-treatment follow-up, 
visit when HCV reinfection risk assessment began (e.g. nd of treatment or SVR), HCV 
testing interval during follow-up, and study quality assessment score. The final adjusted 
model included variables with P<0.10 in unadjusted analyses (0.10 was used as the P value 
cut-off to avoid model instability). Publication bias was assessed using funnel plots and 
Begg’s test. Statistical significances were assessed at P<0.05 (P-values are two sided). All 
analyses were performed using Stata 14.2 (StataCorp, llege Station, TX, USA). 
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RESULTS 
Study selection  
A total of 1,160 records in bibliographic databases and 43 records from other sources were 
identified in the initial search, while 36 eligible studies were eventually included in the 
analysis (Figure 1). 
 
Study characteristics  
Thirty-six studies [20-55] with a total 6,311 person-years follow-up were included (Tables 1 
and 2). Twenty-two studies (61%) reported the propotion of participants with no post-
treatment follow-up assessment (loss to follow-up), which was between zero and 38% 
(median: 10%). In most studies, recent drug use and receiving OAT were defined as drug use 
(n=19) and OAT (n=17) during HCV treatment or post-treatment follow-up. Drug use 
referred to “injecting or non-injecting” drug use in three studies and “injecting only” drug use 
in 32 studies. HCV treatment was interferon-based th rapy in 17 studies, including one study 
for acute HCV infection [41], and DAA therapy in 19 studies. In most studies, HCV 
reinfection assessment started from end of treatment (n=14), or SVR12 (n=11). Diagnosis of 
reinfection was often based on HCV RNA detection following SVR (n=14), or detection of 
different HCV strain using viral sequencing (n=10). 
 
Risk of bias within studies 
The risk of bias assessment scores is shown in Supplementary Table 3. Risk of bias was high 
in four studies (score <6), moderate in 23 studies (score: 6–7), and low in nine studies (score 
>7). 
 
Synthesis of results 
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Data on the rate of HCV reinfection were available for people with recent drug use (injecting 
or non-injecting) in 33 studies (5,061 person-years follow-up) [20-25, 27-37, 39-53, 55], for 
people with injecting drug use in 31 studies (4,648 person-years follow-up) [20-25, 27-36, 
39-44, 46-53, 55], and for those receiving OAT in 25 studies (2,507 person-years follow-up) 
[20, 22, 24-26, 28, 29, 31-35, 38-42, 44-49, 51, 54]. The pooled estimates of reinfection rates 
were 5.9 per 100 person-years (95%CI: 4.1, 8.5) among people with recent injecting or non-
injecting drug use, 6.2 per 100 person-years (95%CI: 4.3, 9.0) among people with recent 
injecting drug use, and 3.8 per 100 person-years (95%CI: 2.5, 5.8) among those receiving 
OAT (Figure 2). High heterogeneity was observed across studies, although lower across 
studies among people receiving OAT (I-square=56.9%), than studies among people with 
recent drug use (I-square=81.4%) and studies among those with recent injecting drug use (I-
square=81.2%; Figure 2). In a sensitivity analysis, excluding two linkage-based Canadian 
studies contributing the largest person-years follow-up [39, 47], the pooled reinfection rates 
slightly increased while heterogeneity decreased (Supplementary Table 4). The funnel plots 
of reinfection rates and the Begg’s test showed no significant evidence of publication bias 
(Supplementary Figure 1). 
 
Twenty-four studies with 3,381 person-years follow-up provided data on the rate of persistent 
HCV reinfection [20, 22, 24-26, 28, 31, 32, 34, 37,8  41-49, 51, 52, 54, 55]. The pooled rate 
estimates were 5.1 per 100 person-years (95%CI: 3.6, 7.1; I-square=58.2%) among people 
with recent drug use, 5.4 per 100 person-years (95% CI: 3.9, 7.5; I-square=51.2%) among 
people with recent injecting drug use, and 3.4 per 100 person-years (95%CI: 2.5, 4.6; I-
square=15.0%), among those receiving OAT.  
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None of the studies reported any case of fulminant hepatitis or acute-on-chronic liver failure 
following HCV reinfection. 
 
Stratified analysis 
Sub-populations of people with recent drug use and those receiving OAT have overlaps given 
that many participants with recent drug use were also receiving OAT. For stratified analysis, 
data of exclusive study population/sub-populations, based on recent drug use and OAT status 
(no overlap) were extracted. For 30 studies, supplementary data were provided by the 
authors. HCV reinfection rates by study population risk groups are illustrated in Figure 3. The 
lowest rate was identified among people receiving OAT, with no recent drug use (1.4 per 100 
person-years; 95%CI: 0.8, 2.6). Increased reinfection rates were identified among people with 
recent drug use who were or were not receiving OAT, with the highest rate identified among 
people with recent drug use, not receiving OAT (6.6 per 100 person-years; 95%CI: 3.4, 12.7; 
Figure 3A). Restricting the analysis to studies providing data on injecting drug use, the results 
were similar (Figure 3B).  
 
Stratified analysis by HCV treatment regimen indicated comparable rates of reinfection 
following interferon-based therapy (5.4 per 100 person-years; 95%CI: 3.1, 9.5) and DAA 
therapy (3.9 per 100 person-years; 95%CI: 2.5, 5.9; Figure 4). 
 
In stratified analysis by risk of bias, no significant difference was observed in rates of 
reinfection across different groups although studies with low risk of bias reported relatively 
higher rates (Supplementary Table 5). 
 
Meta-regression 
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In the adjusted meta-regression model, having a study population with recent drug use was 
associated with a higher rate of reinfection, while gher mean/median age of participants and 
longer mean/median post-treatment follow-up were associated with lower rate of reinfection. 
Compared to people receiving OAT, with no recent drug use, those with recent drug use who 
also received OAT had 3.5 times higher risk of reinfection [adjusted Rate Ratio (RR): 3.50, 
95%CI: 1.62, 7.53; P=0.002), and those with recent drug use, not receiving OAT had four 
times higher risk of reinfection (adjusted RR: 3.96; 5%CI: 1.82, 8.59; P=0.001). Risk of 
reinfection was decreased by 6% for each year increase in mean/median age of study 
participants (adjusted RR: 0.94; 95%CI: 0.91, 0.97; P<0.001), and decreased by 23% by each 
year increase in mean/median post-treatment follow-up (adjusted RR: 0.77; 95%CI: 0.69, 
0.86; P<0.001) (Table 3). Restricting the meta-regression analysis to the studies providing 
data on injecting drug use, no major difference wasob erved in the results. The residual I-
square of the adjusted model was 9%, indicating that t e factors included in the model 
explained a large proportion of heterogeneity across studies (Table 4).  
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DISCUSSION 
This study provides estimates of the rate of reinfection following successful HCV treatment 
among people with recent drug use (5.9 per 100 person-years), people with recent injecting 
drug use (6.2 per 100 person-years), and those receiving OAT (3.8 per 100 person-years). 
Among people with recent drug use, not receiving OAT, the reinfection rate was 6.6 per 100 
person-years. In meta-regression analysis, recent drug use was associated with higher risk of 
reinfection, while older age and longer follow-up was associated with lower risk. This study 
provides robust data on the magnitude of HCV reinfection risk following treatment, 
important to inform HCV clinical guidelines globally and public health policy decisions 
around treatment access and national strategies to guide HCV elimination efforts. 
 
The estimated HCV reinfection rate of 6.2 per 100 person-years among people who have 
recently injected drugs is higher than previous systematic reviews (1.9 to 2.4 per 100 person-
years) [12-14], but consistent with an estimate among people with ongoing injecting drug use 
in the interferon era (6.4 per 100 person-years) [12]. Given the small number of studies, and 
person-years follow-up, this previous estimate is limited by a wide uncertainty range (95% 
CI, 2.5 to 16.7) [12]. Previous systematic reviews have also been limited by inclusion of 
heterogenous study populations with former or current drug use [12, 14], and the small 
number of studies identified (particularly in the DAA era) [12-14]. The large number of 
included studies, and person-years follow-up, and well-defined study populations in this 
study provide a more precise estimate of the rate of HCV reinfection among people with 
recent drug use and those receiving OAT. Moreover, th  considerable efforts made to contact 
the authors to collect supplementary data is a major strength of the current study, enabling 
sub-group and meta-regression analyses.  
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The pooled rate of HCV reinfection among people with recent injecting drug use in this study 
(6.2 per 100 person-years) is lower than reported rates of primary HCV infection in the 
community. In a pooled analysis of seven studies of pe ple who inject drugs from four 
countries, HCV incidence was 23 per 100 person-years, r nging from 7 to 33 per 100 person-
years [3]. The lower rate of HCV reinfection compared to primary infection could be related 
to various factors, including reduced risk behaviors among people who have received HCV 
treatment and a difference in the risk profiles among people at risk of primary infection and 
reinfection, with low-risk individuals more probably engaged in care.  
 
Our finding of significantly lower reinfection risk among people receiving OAT who did not 
use drugs, indicates the importance of enhancing access to OAT as a strategy to prevent 
reinfection. One study demonstrated that lower OAT dose is associated with higher HCV 
incidence [56], suggesting that in addition to improving OAT access, ensuring appropriate 
OAT dosing may also be important for HCV prevention.  
 
This study demonstrated a higher rate of HCV reinfection in studies with shorter follow-up. 
One explanation of this finding is that there is a higher risk of reinfection in the early period 
following treatment completion. Alternatively, this f nding may be due to bias resulting from 
a cohort effect, with high-risk individuals contributing shorter person-years of follow-up due 
to becoming reinfected early post-treatment or losst  follow-up. Future studies of HCV 
reinfection require strategies to enhance study follow-up and ensure there is adequate person-
years of post-treatment follow-up to minimize the potential for bias.  
 
Comparable rates of HCV reinfection were observed following interferon-based and DAA 
therapy in this study. There have been concerns from s me practitioners that the broadening 
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of HCV DAA therapy to more marginalized populations might lead to increased rates of 
reinfection. Further, it has been suggested that the ease and high cure rates of DAA therapy 
might lead to increased risk behaviours among people who inject drugs as compared to 
interferon-based therapies. However, there are now several studies demonstrating that 
injecting risk behaviours remain stable or decrease during and following interferon-based and 
DAA therapy [57-60]. Collectively, these data suggest that there is no difference in the rate of 
reinfection following interferon or DAA therapy.  
 
It should be acknowledged that early stages of HCV treatment scale-up among high-risk 
populations will result in increased HCV reinfection [61]. Rapid scale-up of treatment will 
lead to a greater number of people clearing the virus, thereby increasing the pool of people 
who are susceptible to reinfection and potentially increasing the number of people with 
reinfection. As the prevalence of HCV infection decreases, the numbers with HCV 
reinfection should also decrease. Slow scale-up of treatment has a more limited effect on the 
reservoir of HCV infection, so the numbers with reinf ction will continue to increase. 
Increased numbers of HCV reinfection cases in the context of treatment scale-up should be 
viewed as a marker of high treatment uptake among at-risk populations, but also an indication 
that other harm reduction interventions may need to be intensified [62]. 
 
It should be acknowledged that HCV reinfection following successful treatment can increase 
the overall health system costs within an HCV elimination program since people with HCV 
reinfection require multiple courses of treatment. As such, it is critical to have 
complementary strategies to prevent and manage HCV reinfection [63, 64]. At an individual 
level, prior to initiating DAA therapy, an assessment of HCV reinfection risk should be 
performed by the treating clinician. Management options include identifying populations with 
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potential reinfection risk, education and counselling regarding HCV transmission and drug 
use (particularly the importance of using sterile ne dles/syringes), optimising access to harm 
reduction services [39, 63, 65, 66], treating the individual, their injecting (or sexual) partner 
and people in their injecting network [67], management of medical and psychiatric co-
morbidities [39], post-treatment surveillance [68], and rapid retreatment of reinfection. At a 
population-level, appropriate healthcare provision with universal access to HCV treatment 
and harm reduction services, adequate funding (for both DAA therapy and harm reduction 
programs), and alleviation of the stigma associated with HCV infection and drug use should 
assist in efforts to reduce HCV primary and reinfection incidence. If HCV reinfection does 
occur, retreatment for reinfection should be offered, without stigma or discrimination, to 
reduce further potential transmission.  
 
This study provides the most comprehensive review of HCV reinfection following successful 
treatment among people who inject drugs performed to da e, but has several limitations. A 
high heterogeneity in rates of HCV reinfection was ob erved across studies. The residual I-
square in adjusted meta-regression models were 21% and 9%, indicating that the factors 
included in the model explained a large proportion of heterogeneity across studies. The 
residual heterogeneity may be explained by other factors not considered in our analysis due to 
lack of data, including varying risk profiles or inclusion criteria for study populations, the 
population-level prevalence and incidence of HCV infection, and the coverage of harm 
reduction services. In most studies, all cases of recur ent viraemia following SVR were 
considered as reinfection. Although post-SVR HCV relapse is rare [17, 18], this method 
without using HCV sequencing cannot fully distinguish reinfection from late relapse. In 
several studies, reinfection was diagnosed on the basis of detection of recurrent viraemia with 
different HCV genotype/subtype. In rare occasions, genotype-specific HCV treatment among 
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people with mixed HCV infection (infection with multiple viruses) can result in the 
eradication of one genotype, but not another [69]. Although uncommon, the presence of 
mixed infection in studies defining reinfection based on HCV genotype switch may result in a 
misclassification bias and overestimate the reinfection rate. Several studies conducted 
interventions to reduce risk behaviours following trea ment, such as education of safe 
injection and other preventions, peer-support, counselli g, social support, and provision of 
sterile injecting equipment [22-25, 35, 37, 46, 49, 51, 52]. Given the wide heterogeneity 
between interventions, we were not able to assess th  impact of these interventions on 
reinfection risk. Although assessment of HCV reinfection requires having at least one post-
treatment HCV assessment, several studies did not rep rt or reported a relatively high 
proportion of people lost to follow-up. It is possible that people lost to follow-up and not 
included in analyses had higher risk behaviours for HCV reinfection, leading to a potential 
risk of selection bias towards including people at lower risk of reinfection. Lastly, it is also 
possible that there was a selection bias among people treated for HCV infection in these 
studies representing a less marginalized population, which would underestimate the rate of 
HCV reinfection.  
 
In conclusion, this study demonstrated that post-treatment HCV reinfection occurred, but the 
rate of reinfection in the DAA era was similar to rates observed in the interferon era. 
Although the rate of reinfection was higher in peopl  with recent injecting drug use, it was 
lower than rates of primary infection reported in the community. Monitoring HCV reinfection 
following successful HCV treatment in people who inject drugs will be crucial to HCV 
elimination efforts. Further studies are required to evaluate innovative strategies and models 
of care to enhance engagement in post-treatment care and prevent HCV reinfection among 
people who inject drugs.  
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TABLES  
Table 1: Characteristics of the studies included in analysis 
First author, 
year (country) Study design Setting 
Definition and time point of 
Number of 
participants 
Age 
mean or 
median, 
year 
Proportion of participants 
HCV 
treatment 
Post-treatment follow-up 
Recent drug use OAT 
With 
recent 
drug 
use 
Receiving 
OAT Men 
With 
HIV  
Start 
point 
HCV testing 
schedule 
Duration 
mean or 
median, 
months 
Loss to 
follow-
up 
Person-
years 
follow-
up 
Reinfection diagnosis 
Number of 
HCV 
reinfection 
cases 
Number of 
chronic 
HCV 
reinfection 
cases 
Akiyama, 2018 
(USA)[20] 
Clinical trial 
Drug treatment 
service, 
multicentre 
IDU post-
treatment 
Post-treatment 114 53 19% 100% 61% 10% DAA ETR Every 6 mo 24 19% 230 HCV sequencing 3 2 
Alimohammadi
, 2016 
(Canada)[21] 
Observational, 
retrospective 
Community 
clinic, single 
centre 
IDU during 
treatment 
During 
treatment 
70 53 100% 59% 86% 57% IFN-based SVR12 Every 6 mo 66 NR 385 Post-SVR reviraemia 5 NR 
Backmund, 
2004 
(Germany)[22] 
Observational, 
prospective 
Drug treatment 
service, single 
centre 
IDU at the end of 
treatment 
At treatment 
initiation 
18 32 100% 100% 61% 0% IFN-based SVR24 Every 12 mo 34 6% 49 Post-SVR reviraemia 2 2 
Baxter, 2018 
(UK)[23] 
Observational, 
prospective 
Community 
clinic, single 
centre 
IDU post-
treatment 
NR 19 43 100% NR 89% 0% IFN-based SVR24 Every 12 mo 143 NR 90 Post-SVR reviraemia 2 NR 
Bielen, 2019 
(Belgium)[24] 
Clinical trial 
Drug treatment 
service, single 
centre 
IDU during the 6 
mo pre-treatment 
During the 6 
mo pre-
treatment;  
36 50 36% 100% 83% 0% DAA SVR12 Variable 18 NR 39 HCV genotype switch 1 1 
Bouscaillou, 
2018 
(Georgia)[25] 
Observational, 
prospective 
Drug treatment 
service, single 
centre 
IDU post-
treatment 
Post-treatment 136 47 100% 21% 96% 0% DAA SVR12 Every 6 mo 12 NR 137 Post-SVR reviraemia 2 2 
Boyle, 2018 
(UK)[26] 
Observational, 
retrospective 
Drug treatment 
service, 
multicentre 
IDU or non-IDU 
during 3 mo pre-
treatment 
At treatment 
initiation 
87 45 NR 100% 80% 2% DAA ETR Variable 6 NR 43 NR 1 0 
Coffin, 2019 
(USA)[27] 
Clinical trial 
Community 
clinic, single 
centre 
IDU during 1 
month pre-
treatment 
NR 30 42 100% NR 81% 0% DAA ETR 
After 3, and 
9 mo 
7 3% 18 HCV sequencing 3 NR 
Cuadrado, 
2018 
(Spain)[28] 
Clinical trial 
Prison, single 
centre 
IDU during or 
post-treatment 
During or post-
treatment 
27 39 48% 85% 96% 4% DAA SVR12 Every 6 mo 21 2% 49 HCV sequencing 0 0 
Cunningham, 
2018 (Multi-
country)[29] 
Clinical trial 
Mixed, 
multicentre 
IDU post-
treatment 
At the end of 
treatment 
164 48 76% 68% 72% 0% DAA ETR 
After 3 mo, 
then every 6 
mo 
11 NR 130 HCV sequencing 6 NR 
Dalgard, 2002 
(Norway)[30] Clinical trial 
Mixed, 
multicentre 
IDU post-
treatment NR 9 30 100% 0% 100% 0% IFN-based SVR24 Variable 53 0 40 HCV genotype switch 1 NR 
Deshaies, 2016 
(Canada)[31] 
Observational, 
prospective 
Drug treatment 
service, single 
centre 
IDU during the 6 
mo pre-treatment 
At treatment 
initiation 
30 38 100% 33% 60% 10% IFN-based ETR 
After 3, 6, 
and 12 mo 
31 10% 78 
HCV genotype switch for those 
with reviramemia between ETR 
and SVR24, and any post-
SVR24 reviraemia 
10 10 
Dore, 2017 
(Multi-
country)[32] 
Clinical trial 
Mixed, 
multicentre 
IDU post-
treatment 
Post-treatment 199 49 60% 100% 76% 8% DAA ETR 
After 3 mo, 
then every 6 
mo 
25 33% 528 HCV sequencing 7 6 
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First author, 
year (country) Study design Setting 
Definition and time point of 
Number of 
participants 
Age 
mean or 
median, 
year 
Proportion of participants 
HCV 
treatment 
Post-treatment follow-up 
Recent drug use OAT 
With 
recent 
drug 
use 
Receiving 
OAT Men 
With 
HIV  
Start 
point 
HCV testing 
schedule 
Duration 
mean or 
median, 
months 
Loss to 
follow-
up 
Person-
years 
follow-
up 
Reinfection diagnosis 
Number of 
HCV 
reinfection 
cases 
Number of 
chronic 
HCV 
reinfection 
cases 
Eckhardt, 2018 
(USA)[33] 
Observational, 
prospective 
Drug treatment 
service, single 
centre 
IDU during 1 
month pre-
treatment 
At treatment 
initiation 
45 45 100% 53% 89% 0% DAA SVR12 Every 3 mo 4 NR 16 HCV sequencing 3 NR 
 Grady, 2012 
(Netherlands)[3
4] 
Observational, 
prospective 
Tertiary clinic, 
single centre 
IDU post-
treatment 
During 
treatment 11 47 100% 100% 91% 0% IFN-based ETR Variable 29 0 29 HCV sequencing 1 0 
Grebely, 2010 
(Canada)[35] 
Clinical trial 
Community 
clinic, single 
centre 
IDU post-
treatment 
Post-treatment 16 44 100% 50% 88% 6% IFN-based SVR24 Every 12 mo 21 11% 28 HCV sequencing 2 NR 
Hilsden, 2013 
(Canada)[36] 
Clinical trial 
Community 
clinic, 
multicentre 
IDU during 3 mo 
pre-treatment 
At treatment 
initiation 
23 41 100% NR 75% 0% IFN-based SVR24 NR 22 26% 36 Post-SVR reviraemia 1 NR 
Holeska, 2019 
(Canada)[37] 
Observational, 
retrospective 
Community 
clinic, single 
centre 
IDU or non-IDU 
post-treatment 
NR 195 53 100% 53% 79% 15% DAA SVR12 Every 6 mo 24 6% 379 Post-SVR reviraemia 4 4 
Ingiliz, 2017 
(Germany)[38] 
Observational, 
prospective 
Mixed, 
multicentre 
NR 
At treatment 
initiation 
267 50 NR 100% 76% 25% DAA ETR 
After 1, 3, 
and 6 mo, 
then variable 
6 NR 117 
HCV genotype switch for those 
with reviramemia between ETR 
and SVR12, and any post-
SVR12 reviraemia 
2 1 
Islam, 2017 
(Canada)[39] 
Observational, 
retrospective* 
Mixed, 
multicentre 
IDU during 3 yr 
pre-SVR or 
anytime post-
treatment 
Post-treatment 399 43 84% 35% 66% 12% IFN-based SVR12 Variable 55 NR 1952 Post-SVR reviraemia 22 NR 
Marco, 2013 
(Spain)[40] 
Observational, 
prospective 
Prison, 
multicentre 
IDU during or 
post-treatment 
During or post-
treatment 
59 32 20% 80% 97% 19% IFN-based SVR24 Every 12 mo 20 2% 76 Post-SVR reviraemia 6 NR 
Martinello, 
2017 
(Australia)[41] 
Clinical trial 
Mixed, 
multicentre 
IDU at the end or 
post-treatment 
At treatment 
initiation 
45 34 100% 24% 84% 31% DAA** ETR 
After 1, and 
3 mo, then 
every 6 mo 
15 4% 52 
HCV sequencing for those with 
reviramemia between ETR and 
SVR12/24, and any post-
SVR12/24 reviraemia 
8 4 
Midgard, 2016 
(Norway)[43] 
Clinical trial 
Mixed, 
multicentre 
IDU post-
treatment 
NR 37 33 100% NR 62% 0% IFN-based SVR24 Variable 82 14% 206 
HCV sequencing; If not 
available any post-SVR24 
reviraemia in a patient who had 
recent IDU 
12 10 
Midgard, 2018 
(Norway)[42] 
Observational, 
prospective 
Community 
clinic, single 
centre 
IDU during 3 mo 
pre-treatment 
At treatment 
initiation 83 48 100% 22% 78% 0% DAA ETR Every 3 mo 10 NR 71 Post-SVR reviraemia 2 2 
Pineda, 2015 
(Spain)[45] 
Observational, 
retrospective 
Tertiary clinic, 
multicentre 
IDU or non-IDU 
post-treatment 
Post-treatment 11 46 100% 64% 100% 100% IFN-based SVR24 Every 6 mo 32 24% 34 HCV sequencing 3 3 
Rosenthal, 
2018 
(USA)[46] 
Clinical trial 
Tertiary clinic, 
single centre 
IDU during 3 mo 
pre-treatment 
During or post-
treatment 
79 58 100% 91% 75% 4% DAA ETR 
After 3 mo, 
then every 6 
mo 
9 NR 52 
HCV genotype switch for those 
with reviramemia between ETR 
and SVR12, and any post-
SVR12 reviraemia 
3 3 
Rossi, 2018 
(Canada)[47] 
Observational, 
retrospective* 
Mixed, 
multicentre 
IDU during 3 yr 
pre-SVR 
At the end or 
post-treatment 
909 58 96% 7% 67% 19% DAA 
SVR12/
24 
Variable 6 22% 697 Post-SVR reviraemia 22 18 
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First author, 
year (country) Study design Setting 
Definition and time point of 
Number of 
participants 
Age 
mean or 
median, 
year 
Proportion of participants 
HCV 
treatment 
Post-treatment follow-up 
Recent drug use OAT 
With 
recent 
drug 
use 
Receiving 
OAT Men 
With 
HIV  
Start 
point 
HCV testing 
schedule 
Duration 
mean or 
median, 
months 
Loss to 
follow-
up 
Person-
years 
follow-
up 
Reinfection diagnosis 
Number of 
HCV 
reinfection 
cases 
Number of 
chronic 
HCV 
reinfection 
cases 
Scherz, 2018 
(Switzerland)[4
8] 
Observational, 
retrospective 
Tertiary clinic, 
single centre 
IDU post-
treatment 
Post-treatment 39 49 31% 100% 82% 10% DAA SVR12 Variable 16 NR 45 HCV genotype switch 2 2 
Schubert, 2018 
(Austria)[49] 
Observational, 
prospective 
Tertiary clinic, 
single centre 
IDU during 3 yr 
pre-SVR 
At the end or 
post-treatment 
178 39 75% 100% 82% 10% DAA SVR12 Every 3 mo 13 NR 192 HCV genotype switch 11 10 
Schulkind, 
2018 (UK)[50] 
Observational, 
prospective 
Tertiary clinic, 
single centre 
IDU during 1 
week pre-
treatment 
During 
treatment 
77 35 100 72 72% 0% IFN-based SVR12 After 3, and 
12 mo 
11 1% 68 Post-SVR reviraemia 15 NR 
Selfridge, 2019 
(Canada)[51] 
Observational, 
retrospective 
Primary care, 
single centre 
IDU during the 6 
mo pre-treatment 
At treatment 
initiation 
159 53 78% 74% 68% 24% DAA ETR Variable 10 6% 167 
HCV genotype switch for those 
with reviramemia between ETR 
and SVR12, and any post-
SVR12 reviraemia 
8 8 
Valencia, 2019 
(Spain)[52] 
Observational, 
prospective 
Drug treatment 
service, 
multicentre 
IDU during the 6 
mo pre-treatment 
NR 87 45 100% NR 72% 44% DAA ETR Variable 8 24% 60 
HCV genotype switch for those 
with reviramemia between ETR 
and SVR12, and any post-
SVR12 reviraemia 
10 8 
Weir, 2016 
(UK)[53] 
Observational, 
retrospective* 
Mixed, 
multicentre 
IDU post-
treatment 
NR 29 38 100% NR 79% 7% IFN-based 
1 yr 
post-
treatmen
t  
Variable 86 38% 88 Post-SVR reviraemia 5 NR 
Xynotroulas, 
2015 
(Greece)[54] 
Observational, 
retrospective 
Tertiary clinic, 
single centre 
IDU during or 
post-treatment 
At the end or 
post-treatment 
30 33 17% 100% 80% 0% IFN-based 
SVR12/
24 
Variable 7 NR 18 Post-SVR reviraemia 1 1 
Young, 2017 
(Canada)[55] 
Observational, 
prospective 
Mixed, 
multicentre 
IDU during or 
post-treatment 
NR 42 47 100% NR 87% 100% DAA† SVR12 Every 6 mo 18 19% 96 Post-SVR reviraemia 9 6 
Øvrehus, 2018 
(Denmark)[44] 
Clinical trial 
Drug treatment 
service, single 
centre 
IDU during 1 
month pre-
treatment 
At treatment 
initiation 
31 39 35% 100% 81% 0% DAA‡ ETR 
After 1, 3, 
and 6 mo, 
then variable 
6 10% 13 HCV sequencing 1 1 
 
OAT: opiod agonist therapy; IDU: injecting drug use; Non-IDU: non-injecting drug use; DAA: direct-acting antiviral agent; SVR: sustained virologic response; NR: Not reported 
* Data linkage study 
** Acute HCV infection; 4 participants (9%) received DAA therapy 
† 4 participants (10%) received DAA therapy 
‡ 15 participants (50%) received sofosbuvir/ledipaspir + Pegylated IFN 
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Table 2: Cumulative summary characteristics of the studies, included in analysis 
  Study n (%) Person-years follow-up 
Study design     
   Clinical trial 13 (36) 1,421 
   Observational study, prospective 13 (36) 1,082 
   Observational study, retrospective 7 (19) 1,071 
   Observational study, retrospective linkage 3 (8) 2,737 
Study setting     
   Drug treatment service 13 (36) 1,024 
   Community clinic 7 (19) 1,007 
   Tertiary care 3 (8) 82 
   Prison 2 (6) 125 
   Primary care 1 (3) 167 
   Mixed setting 10 (28) 3,907 
Single- or multi-centre     
   Single-centre 20 (56) 1,925 
   Multi-centre 16 (44) 4,386 
Study population     
   All participants had recent drug use and received OAT 2 (6) 78 
   All participants had recent drug use; some received OAT 15 (42) 1,701 
   All participants had recent drug use; none received OAT 1 (3) 40 
   All participants had recent drug use; OAT status not reported 3 (8) 196 
   All participants received OAT; some had recent drug use 8 (22) 1,107 
   All participants received OAT; recent drug use status not reported 1 (3) 117 
   Some participants received OAT; some had recent drug use 6 (17) 3,072 
Drug use type     
   Injecting drug use 32 (89) 5,738 
   Injecting or non-injecting drug use 3 (8) 456 
   Not reported 1 (3) 117 
Definition of “recent drug use”     
   During HCV treatment or post-treatment follow-up 19 (53) 2,641 
   At the time of or during the 1-6 months before HCV treatment initiation 14 (39) 904 
   Other 2 (6) 2,649 
   Not reported 1 (3) 117 
Definition of “receiving OAT”     
   During HCV treatment or post-treatment follow-up 17 (47) 4,653 
   At the time of HCV treatment initiation 10 (28) 642 
   During the 6 months before HCV treatment initiation 1 (3) 39 
   Not reported 8 (22) 977 
HCV treatment     
   Interferon-based therapy 17 (47) 3,327 
   Direct-acting antiviral therapy 19 (53) 2,984 
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  Study n (%) Person-years follow-up 
Start point for reinfection assessment     
   End of treatment 14 (39) 1,589 
   12 weeks post-treatment (SVR12) 11 (31) 3,361 
   12-24 weeks post-treatment (SVR12/24) 2 (6) 715 
   24 weeks post-treatment (SVR24) 8 (22) 559 
   Other 1 (3) 88 
HCV reinfection diagnosis method     
   Recurrent viraemia following SVR 14 (39) 4,144 
   Detection of different HCV strain using sequencing 10 (28) 1,076 
   Detection of different HCV genotype/subtype 4 (11) 316 
   HCV sequencing or genotype switch in recurrent viraemia between end 
of treatment and SVR + any recurrent viraemia following SVR 6 (17) 526 
   Other 1 (3) 206 
   Not reported 1 (3) 43 
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Table 3: Meta-regression analysis of study-level factors associated with HCV reinfection rate 
 Number of 
studies/sub-
studies 
Unadjusted models Adjusted model* 
Rate Ratio (95% CI) P Rate Ratio (95% CI) P 
Proportion of men, per 10% increase 61 1.08 (0.84, 1.39) 0.529   
Median/mean age, per year increase 61 0.95 (0.91, 0.98) 0.002 0.94 (0.91, 0.97) <0.001 
Proportion of participants with HIV co-
infection, per 10% increase 
61 1.04 (0.93, 1.17) 0.452   
Study design 61     
  Observational study, retrospective 18 1.00  1.00  
  Observational study, prospective 19 2.62 (1.37, 4.98) 0.004 1.36 (0.76, 2.42) 0.294 
  Clinical trial 24 2.01 (1.05, 3.85) 0.036 1.28 (0.74, 2.23) 0.371 
Study setting 61     
   Tertiary care, primary care or community 
clinic 
16 1.00    
   Drug treatment service 22 1.73 (0.83, 3.60) 0.141   
   Prison 5 1.72 (0.48, 6.22) 0.402   
   Mixed setting 18 0.82 (0.39, 1.70) 0.587   
HCV treatment 61     
   Interferon-based therapy 24 1.00    
   Direct-acting antiviral therapy 37 0.78 (0.44, 1.42) 0.412   
Study population 61     
   OAT: yes, DU: no 12 1.00  1.00  
   OAT: yes, DU: unknown 3 1.81 (0.37, 8.88) 0.456 1.16 (0.27, 4.90) 0.841 
   OAT: yes, DU: yes 21 4.03 (1.59, 10.21) 0.004 3.50 (1.62, 7.53) 0.002 
   OAT: unknown, DU: yes 10 3.99 (1.48, 10.74) 0.007 5.69 (2.53, 12.78) <0.001 
   OAT: no DU: yes 15 4.52 (1.71, 11.93) 0.003 3.96 (1.82, 8.59) 0.001 
Median/mean follow-up, per year increase 61 0.87 (0.76, 0.99) 0.032 0.77 (0.69, 0.86) <0.001 
Start point for reinfection assessment 61     
   12 weeks post-treatment (SVR) or later 36 1.00    
   End of treatment 25 1.39 (0.78, 2.51) 0.261   
HCV testing interval, per month increase 48 1.01 (0.98, 1.04) 0.636   
Study quality assessment score 61 1.30 (0.95, 1.78) 0.098 0.99 (0.74, 1.31) 0.926 
DU: Injecting or non-injecting drug use; OAT: Opioid agonist therapy; SVR: Sustained virological respon e 
*Includes variables with P<0.1 in unadjusted models (61 studies/substudies included); Residual I-square=20.65% 
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Table 4: Meta-regression analysis of study-level factors associated with HCV reinfection rate, in studies 
providing data on injecting drug use among participants 
 Number of 
studies/sub-
studies 
Unadjusted models Adjusted model* 
Rate Ratio (95% CI) P Rate Ratio (95% CI) P 
Proportion of men, per 10% increase 55 1.04 (0.80, 1.36) 0.747   
Median/mean age, per year increase 55 0.95 (0.92, 0.99) 0.007 0.95 (0.92, 0.97) <0.001 
Proportion of participants with HIV co-
infection, per 10% increase 
55 1.03 (0.89, 1.19) 0.699   
Study design 55     
  Observational study, retrospective 13 1.00  1.00  
  Observational study, prospective 18 3.11 (1.59, 6.11) 0.001 1.36 (0.75, 2.48) 0.303 
  Clinical trial 24 2.20 (1.12, 4.33) 0.023 1.31 (0.75, 2.26) 0.331 
Study setting 55     
   Tertiary care, primary care or community 
clinic 
12 1.00    
   Drug treatment service 21 1.78 (0.80, 3.98) 0.157   
   Prison 5 1.70 (0.45, 6.39) 0.422   
   Mixed setting 17 0.84 (0.37, 1.87) 0.660   
HCV treatment 55     
   Interferon-based therapy 21 1.00    
   Direct-acting antiviral therapy 34 0.91 (0.49, 1.70) 0.775   
Study population 55     
   OAT: yes, IDU: no 12 1.00  1.00  
   OAT: yes, IDU: yes 20 4.08 (1.62, 10.29) 0.004 3.47 (1.65, 7.32) 0.002 
   OAT: unknown, IDU: yes 9 4.83 (1.78, 13.07) 0.003 6.81 (3.08, 15.01) <0.001 
   OAT: no IDU: yes 14 4.22 (1.60, 11.15) 0.004 3.74 (1.77, 7.89) 0.001 
Median/mean follow-up, per year increase 55 0.85 (0.75, 0.97) 0.017 0.76 (0.69, 0.84) <0.001 
Start point for reinfection assessment 55     
   12 weeks post-treatment (SVR) or later 32 1.00    
   End of treatment 23 1.52 (0.83, 2.79) 0.175   
HCV testing interval, per month increase 43 1.01 (0.97, 1.04) 0.677   
Study quality assessment score 55 1.34 (0.94, 1.92) 0.107   
IDU: Injectiong drug use; OAT: Opioid agonist therapy; SVR: Sustained virological response  
*Includes variables with P<0.1 in unadjusted models (61 studies/substudies included); Residual I-square=8.95% 
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FIGURE LEGENDS  
 
Fig. 1. Flow diagram detailing the review process and study 
 
Fig. 2. Forest plots of studies, evaluating HCV reinfection rate following HCV treatment 
(A) Among people with recent injecting or non-injecting drug use; (B) Among people with 
recent injecting drug use; (C) Among people receiving OAT 
DU: recent drug use (injecting or non-injecting); IDU: recent injecting drug use; OAT: opioid 
agonist therapy 
 
Fig. 3. Forest plots of studies, evaluating HCV reinfection rate following HCV 
treatment, stratifyed by study population/sub-population 
(A) Based on recent drug use (injecting or non-injecting) and OAT status; (B) Based on 
injecting drug use and OAT status 
DU: recent drug use (injecting or non-injecting); IDU: recent injecting drug use; OAT: opioid 
agonist therapy 
 
Fig. 4. Forest plots of studies, evaluating HCV reinfection rate following HCV 
treatment, stratifyed by HCV treatment regimen 
IFN: Interferon; DAA: direct-acting antiviral 
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Cuadrado, 2018
OAT:no, DU:yes
Pineda, 2015
Cunningham, 2018
Pineda, 2015
Scherz, 2017
Grebely, 2010
Bouscaillou, 2018
Subtotal  (I-squared = 81.9%, p = 0.000)
Dore, 2017
Islam, 2017
Cunningham, 2018
Young, 2017
Schubert, 2018
OAT:yes, DU:no
Hilsden, 2013
Cuadrado, 2018
Scherz, 2017
Subtotal  (I-squared = 85.2%, p = 0.000)
Coffin, 2019
Schulkind, 2018
OAT:yes, DU:unknown
Deshaies, 2016
Baxter, 2018
Midgard, 2018
Akiyama, 2018
Dalgard, 2002
Martinello, 2017
Akiyama, 2018
Boyle, 2018
Valencia, 2019
Eckhardt, 2018
Holeska, 2019
Grady, 2012
Schubert, 2018
Marco, 2013
ID
Selfridge, 2019
OAT:yes, DU:yes
Martinello, 2017
Øvrehus, 2018
Xynotroulas, 2015
Selfridge, 2019
Ingiliz, 2017
Cuadrado, 2018
Rosenthal, 2018
Bielen, 2019
Øvrehus, 2018
Rossi, 2018
Dore, 2017
Cunningham, 2018
Bielen, 2019
OAT:unknown, DU:yes
Deshaies, 2016
Backmund, 2004
Islam, 2017
Eckhardt, 2018
Selfridge, 2019
Weir, 2016
Study
4.8 (3.6, 6.5)
1.4 (0.7, 2.6)
1.8 (0.5, 7.3)
1.3 (0.5, 3.1)
5.9 (4.0, 8.6)
2.5 (0.9, 6.6)
1.2 (0.7, 1.9)
3.2 (0.2, 51.6)
4.5 (0.6, 32.3)
5.8 (3.3, 10.3)
1.6 (0.1, 26.2)
33.0 (13.7, 79.3)
13.3 (3.3, 53.3)
10.2 (0.6, 163.1)
2.8 (0.2, 45.4)
17.2 (4.3, 68.9)
1.7 (0.2, 12.1)
4.4 (0.6, 31.1)
2.8 (0.4, 19.7)
3.8 (0.2, 61.5)
1.7 (0.1, 27.7)
6.6 (3.4, 12.7)
0.3 (0.0, 2.2)
1.3 (0.5, 3.2)
10.5 (4.4, 25.2)
9.4 (4.9, 18.0)
7.4 (4.0, 13.7)
2.8 (0.4, 19.7)
2.0 (0.1, 32.4)
11.1 (1.6, 78.9)
5.7 (2.9, 11.0)
16.3 (5.3, 50.5)
21.5 (13.0, 35.7)
16.4 (7.8, 34.4)
2.2 (0.6, 8.9)
3.6 (0.9, 14.3)
0.3 (0.0, 4.2)
2.5 (0.4, 17.7)
12.8 (5.3, 30.8)
7.4 (2.4, 22.9)
2.3 (0.3, 16.6)
16.7 (9.0, 31.0)
11.9 (0.7, 190.3)
1.1 (0.4, 2.8)
3.4 (0.5, 24.4)
1.8 (0.3, 12.7)
1.6 (0.2, 11.6)
re-infection rate (95% CI)
5.5 (2.3, 13.1)
22.6 (7.3, 70.1)
22.5 (3.2, 160.1)
5.6 (0.8, 39.4)
6.7 (2.2, 20.7)
1.7 (0.4, 6.8)
6.0 (0.4, 95.2)
6.3 (2.0, 19.6)
8.3 (1.2, 59.2)
5.8 (0.4, 93.3)
3.3 (2.1, 5.0)
2.8 (1.3, 6.3)
2.0 (0.1, 32.7)
1.8 (0.1, 29.1)
8.5 (2.7, 26.2)
4.1 (1.0, 16.4)
0.7 (0.2, 2.9)
23.8 (7.7, 73.8)
1.6 (0.1, 25.6)
5.7 (2.4, 13.7)
HCV
.
100.00
7.05
10.35
100.00
100.00
9.63
3.65
10.00
11.56
1.66
8.65
4.77
3.65
1.66
7.05
2.93
2.93
10.00
3.65
1.66
100.00
10.00
7.64
8.65
11.25
9.55
6.04
5.00
2.93
100.00
9.25
11.75
9.04
8.17
4.77
5.00
5.38
8.65
6.03
25.00
11.37
3.65
9.91
2.93
10.00
10.00
Weight
7.64
6.03
2.93
25.00
7.86
50.00
3.65
6.03
2.93
5.00
9.78
8.18
5.00
5.00
6.03
4.77
20.00
6.03
5.00
10.35
%
  
.01 .5 1 2 4 8 16 32 64
Rate (per 100 person-year)
HCV re-infection rate, by drug use/OAT status
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 72.5%, p = 0.000)
OAT:yes, IDU:yes
Cunningham, 2018
Bouscaillou, 2018
Subtotal  (I-squared = 81.7%, p = 0.000)
Alimohammadi, 2016
Cuadrado, 2018
Cuadrado, 2018
Deshaies, 2016
Baxter, 2018
Midgard, 2018
Cunningham, 2018
Subtotal  (I-squared = 0.0%, p = 0.746)
Grebely, 2010
Rossi, 2018
Bouscaillou, 2018
Backmund, 2004
Marco, 2013
OAT:no, IDU:yes
Islam, 2017
Selfridge, 2019
OAT:yes, IDU:no
Dore, 2017
Coffin, 2019
Subtotal  (I-squared = 82.4%, p = 0.000)
Midgard, 2016
Deshaies, 2016
ID
Study
OAT:unknown, IDU:yes,
Grady, 2012
Dore, 2017
Rosenthal, 2018
Weir, 2016
Martinello, 2017
Øvrehus, 2018
Eckhardt, 2018
Young, 2017
Scherz, 2017
Selfridge, 2019
Schubert, 2018
Rosenthal, 2018
Rossi, 2018
Midgard, 2018
Valencia, 2019
Cuadrado, 2018
Marco, 2013
Bielen, 2019
Eckhardt, 2018
Akiyama, 2018
Subtotal  (I-squared = 45.5%, p = 0.015)
Islam, 2017
Schulkind, 2018
Martinello, 2017
Grebely, 2010
Cunningham, 2018
Islam, 2017
Bielen, 2019
Hilsden, 2013
Schubert, 2018
Dalgard, 2002
Selfridge, 2019
Akiyama, 2018
Rossi, 2018
Øvrehus, 2018
Scherz, 2017
5.1 (3.7, 6.9)
1.7 (0.2, 12.1)
1.8 (0.5, 7.3)
6.9 (3.7, 12.9)
1.3 (0.5, 3.1)
2.0 (0.1, 32.4)
6.0 (0.4, 95.2)
8.5 (2.7, 26.2)
2.2 (0.6, 8.9)
3.6 (0.9, 14.3)
2.0 (0.1, 32.7)
1.4 (0.7, 2.6)
13.3 (3.3, 53.3)
3.3 (2.1, 5.0)
1.7 (0.1, 27.7)
4.1 (1.0, 16.4)
1.6 (0.2, 11.6)
0.7 (0.2, 2.9)
5.5 (2.3, 13.1)
2.8 (1.3, 6.3)
16.3 (5.3, 50.5)
6.1 (3.1, 12.1)
5.8 (3.3, 10.3)
16.4 (7.8, 34.4)
re-infection rate (95% CI)
HCV
3.4 (0.5, 24.4)
0.3 (0.0, 2.2)
10.2 (0.6, 163.1)
5.7 (2.4, 13.7)
22.6 (7.3, 70.1)
22.5 (3.2, 160.1)
11.9 (0.7, 190.3)
9.4 (4.9, 18.0)
11.1 (1.6, 78.9)
6.7 (2.2, 20.7)
7.4 (4.0, 13.7)
6.3 (2.0, 19.6)
4.5 (0.6, 32.3)
3.2 (0.2, 51.6)
16.7 (9.0, 31.0)
2.8 (0.2, 45.4)
33.0 (13.7, 79.3)
8.3 (1.2, 59.2)
23.8 (7.7, 73.8)
0.3 (0.0, 4.2)
5.9 (4.0, 8.8)
1.2 (0.7, 1.9)
21.5 (13.0, 35.7)
12.8 (5.3, 30.8)
3.8 (0.2, 61.5)
10.5 (4.4, 25.2)
1.3 (0.5, 3.2)
1.8 (0.1, 29.1)
2.8 (0.4, 19.7)
1.8 (0.3, 12.7)
2.5 (0.4, 17.7)
1.6 (0.1, 25.6)
7.4 (2.4, 22.9)
1.6 (0.1, 26.2)
5.8 (0.4, 93.3)
2.8 (0.4, 19.7)
.
3.08
7.58
100.00
11.48
5.00
3.93
6.20
8.57
4.95
5.00
100.00
4.95
10.52
1.75
4.95
10.00
20.00
7.78
8.31
9.98
100.00
13.23
9.73
Weight
%
3.08
10.00
3.93
11.48
6.20
3.08
3.93
12.77
3.08
8.45
9.61
6.20
10.00
3.93
12.95
1.75
9.30
3.08
6.20
5.00
100.00
10.35
13.52
9.30
3.93
9.30
7.78
5.00
6.03
10.00
5.79
5.00
6.20
1.75
5.00
10.00
  
.01 .5 1 2 4 8 16 32 64
Rate (per 100 person-year)
HCV re-infection rate, by injecting drug use/OAT status
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 80.8%, p = 0.000)
Midgard, 2018
Martinello, 2017
Dore, 2017
Cunningham, 2018
Boyle, 2018
Rossi, 2018
Rosenthal, 2018
Alimohammadi, 2016
Midgard, 2016
Øvrehus, 2018
Cuadrado, 2018
Ingiliz, 2017
Coffin, 2019
Bielen, 2019
Marco, 2013
Selfridge, 2019
Study population received DAA treatment
Eckhardt, 2018
Valencia, 2019
Hilsden, 2013
Islam, 2017
Schulkind, 2018
ID
Akiyama, 2018
Bouscaillou, 2018
Grady, 2012
Schubert, 2018
Pineda, 2015
Scherz, 2017
Grebely, 2010
Deshaies, 2016
Subtotal  (I-squared = 70.8%, p = 0.000)
Xynotroulas, 2015
Backmund, 2004
Subtotal  (I-squared = 86.3%, p = 0.000)
Weir, 2016
Dalgard, 2002
Baxter, 2018
Holeska, 2019
Young, 2017
Study population received IFN-based treatment
Study
4.6 (3.2, 6.5)
2.8 (0.7, 11.3)
15.3 (7.7, 30.6)
1.3 (0.6, 2.8)
4.6 (2.1, 10.2)
2.3 (0.3, 16.6)
3.2 (2.1, 4.8)
5.8 (1.9, 18.0)
1.3 (0.5, 3.1)
5.8 (3.3, 10.3)
8.0 (1.1, 56.8)
1.0 (0.1, 16.1)
1.7 (0.4, 6.8)
16.3 (5.3, 50.5)
2.6 (0.4, 18.2)
7.9 (3.5, 17.5)
4.8 (2.4, 9.6)
18.3 (5.9, 56.7)
16.7 (9.0, 31.0)
2.8 (0.4, 19.7)
1.1 (0.7, 1.7)
21.5 (13.0, 35.7)
re-infection rate (95% CI)
1.3 (0.4, 4.0)
1.5 (0.4, 5.8)
3.4 (0.5, 24.4)
5.7 (3.2, 10.3)
8.7 (2.8, 27.0)
4.4 (1.1, 17.8)
7.3 (1.8, 29.1)
12.8 (6.9, 23.8)
3.9 (2.5, 5.9)
5.6 (0.8, 39.4)
4.1 (1.0, 16.4)
5.4 (3.1, 9.5)
5.7 (2.4, 13.7)
2.5 (0.4, 17.7)
2.2 (0.6, 8.9)
1.1 (0.4, 2.8)
9.4 (4.9, 18.0)
HCV
.
4.52
6.90
6.89
6.66
3.05
8.04
5.38
6.50
7.15
3.05
1.85
4.52
5.38
3.05
6.67
7.08
5.38
7.35
3.99
7.39
7.25
Weight
5.38
4.52
3.99
7.46
5.88
4.52
5.26
7.05
100.00
3.99
5.26
100.00
6.50
3.99
5.26
5.95
6.98
%
  
.01 .5 1 2 4 8 16 32 64
Rate (per 100 person-year)
HCV re-infection rate by HCV treatment regimen
Highlights 
• In this systematic review, we assessed the rate of HCV reinfection after treatment 
among people who recently used drugs or received opioid agonist therapy. 
• The rate of reinfection was lowest among people receiving opioid agonist therapy 
with no recent drug use, compared to people with recent drug use. 
• The rate of HCV reinfection was comparable between post-interferon therapy, and 
post-direct acting antiviral therapy.  
• A higher rate of HCV reinfection was observed in studies with shorter follow-up 
 
